Drug repurposing for glucosyltransferase inhibition for targeted oral biofilm disruption
Fernanda S. de Lucena, Matthew G. Logan, Steven H. Lewis, Hua Zhang, Matthew Barbisan, Marcelo Y. Icimoto, Hui Wu, Dustin Higashi, Justin L. Merritt, Jonathon L. Baker, Carmem S. Pfeifer · 2026
Read Drug repurposing for glucosyltransferase inhibition for targeted oral biofilm disruption by Fernanda S. de Lucena, Matthew G. Logan, Steven H. Lewis, Hua Zhang, Matthew Barbisan, Marcelo Y. Icimoto, Hui Wu, Dustin Higashi, Justin L. Merritt, Jonathon L. Baker, Carmem S. Pfeifer (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13438108.txt.
Description
Fernanda de Lucena and co-authors repurpose existing drugs to block glucosyltransferase and disrupt oral biofilm. Their 2026 paper deals with Streptococcus mutans, the bacterium behind much tooth decay.
This bacterium builds a sugar-rich biofilm using enzymes called glucosyltransferases, which make soluble and insoluble glucans on its surface. One enzyme, GtfC, is essential for biofilm start and cohesion, so it was chosen as the drug target. Commercial drugs were screened in silico, then tested in biofilm assays. Two leads, radotinib and pranlukast, cut biofilm mass sharply. One of them also killed the target bacterium while sparing helpful species, a useful trait for oral use.
Catalog record
| CREATOR | Fernanda S. de Lucena, Matthew G. Logan, Steven H. Lewis, Hua Zhang, Matthew Barbisan, Marcelo Y. Icimoto, Hui Wu, Dustin Higashi, Justin L. Merritt, Jonathon L. Baker, Carmem S. Pfeifer |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 68 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |